GlassScriptPhysician profile
Everett C Mckibben
NPI 1093873713
$2,075.16
in general payments reported to CMS, 2019-2025
29 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $416 · 2021: $522 · 2022: $223 · 2023: $207 · 2024: $170 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $562.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $338.81 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $246.06 | 2019-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $234.68 | 2020-2022 | |
| Pfizer INC. | $199.02 | 2019-2025 | |
| Lilly USA, LLC | $144.58 | 2020-2022 | |
| Mylan Specialty L.P. | $104.17 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $100.98 | 2019-2021 | |
| Abbott Laboratories | $99.81 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.36 | 2020-2021 | |
| Daiichi Sankyo INC. | $57.40 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $45.83 | 2023-2025 | Breztri, Farxiga |
| Sanofi Pasteur INC. | $44.45 | 2019-2023 | |
| Global Blood Therapeutics, INC. | $36.97 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.92 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.11 | 2024-2025 | Caplyta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.45 | 2022-2023 | Shingrix, Arexvy |
| Allergan, INC. | $27.56 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $24.25 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $23.41 | 2023 | Zilretta |
| Greenwich Biosciences, INC. | $21.66 | 2021 | |
| Dexcom, INC. | $19.77 | 2021 | |
| Ibsa Pharma INC. | $18.02 | 2025 | Flector, Tirosint, Licart |
| Biohaven Pharmaceutical Holding Company LTD. | $16.32 | 2022 | |
| Seqirus USA INC | $16.25 | 2024 | Flucelvax, Fluad |
| Merck Sharp & Dohme LLC | $15.84 | 2025 | Capvaxive |
| Melinta Therapeutics, LLC | $14.75 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.67 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Everett Mckibben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.